SUPPRESSION OF THE GROWTH HORMONE/INSULIN-LIKE GROWTH FACTOR-1 (GH/IGF-1) AXI

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是一项针对患有风湿性关节炎(RA)的绝经前妇女的为期6个月的开放式标签试点研究，将在马里兰州巴尔的摩约翰·霍普金斯海湾医学中心的综合临床研究中心(GCRC)和美国国立卫生研究院的临床中心进行。这项研究将探索系统性释放的炎性细胞因子对GH/IGF-1轴抑制的可能影响，以及内分泌免疫功能改变与身体成分、代谢和血管功能的关系，这些功能被认为与RA相关的骨量减少、骨量减少和心血管疾病风险增加有关。在研究的第一阶段，我们将让RA患者和对照受试者在临床中心进行为期36小时的GH/IGF-1轴、细胞因子、身体成分、内分泌代谢和心血管功能以及生活质量的评估。在研究的第二阶段，我们将在使用Etanercept治疗RA患者6个月后重新评估上述结果指标。Etanercept是一种可溶性p75肿瘤坏死因子受体分子，最近被FDA批准用于治疗早期RA患者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a 6-month, open label, pilot study in pre-menopausal women with rheumatoid arthritis (RA) of less than 3 years duration to be conducted at the General Clinical Research Center (GCRC) of the Johns Hopkins Bayview Medical Center, Baltimore, MD and the Clinical Center of National Institutes of Health. This investigation will explore the possible impact of systematically released inflammatory cytokines on suppression of the GH/IGF-1 axis, and the relationships of altered endocrine-immune function with body composition, metabolic and vascular functions thought to be associated with RA-related sarcopenia, osteopenia, and increased risk of cardiovascular disease. In phase I of the study, we shall admit RA patients and control subjects to the Clinical Center for a 36 hour period for assessments of the GH/IGF-1 axis, cytokines, body composition, endocrine-metabolic and cardiovascular functions, and quality of life. In Phase II of the study, we shall re-evaluate the above outcome measures after six months of treatment of the RA patients with Etanercept, a soluble p75 TNF receptor molecule, which has recently been approved by the FDA for the treatment of patients with early RA.